Leptin as a Potential Treatment for Obesity: Progress to Date
Abstract
Despite significant reductions in the consumption of dietary fat, the prevalence of obesity is steadily rising in western civilization. Of particular concern is the recent epidemic of childhood obesity, which is expected to increase the incidence of obesity-related disorders. The obese gene (ob) protein product leptin is a hormone that is secreted from adipocytes and functions to suppress appetite and increase energy expenditure. Leptin is an attractive candidate for the treatment of obesity as it is an endogenous protein and has been demonstrated to have potent effects on bodyweight and adiposity in rodents. Whereas leptin has been successfully used in the treatment of leptin-deficient obese patients, trials in hyperleptinemic obese patients have yielded variable results. Long-acting leptins have been tried but with no greater success. Other strategies including the use of leptin analogs and other factors that bypass normal leptin delivery systems are being developed. Identifying the mechanisms at the molecular level by which leptin functions will create new avenues for pharmaceutical targeting to simulate the intracellular effects of leptin.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Leptin therapy has been associated with marked reversal of the obesity phenotype in ob/ob mice, whereas administration of leptin has been largely ineffective in treating human obesity.
“To further emphasize this point, leptin therapy has been associated with marked reversal of the obesity phenotype in ob/ob mice, whereas administration of leptin has unfortunately been largely ineffective in treating human obesity (27).”
From Cardiac remodeling in obesity (2008) · cites this paper as [27]
The citation lists haven’t been fetched yet
References 73 · Cited by 36
- Authors
- Bell-Anderson, K. S., & Bryson, J. M.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Bell-Anderson, Kim S
- ORCID
- Bell-Anderson, Kim S
- Venue
- Treatments in Endocrinology
- Published
- 2004
- Volume
- 3
- Issue
- 1
- Pages
- 11-18
- ISSN
- 1175-6349 (ISSN-L)
- OpenAlex
- W2071684485
- Cited by
- 36
- References
- 73
- Citations by year
- 2022: 1 · 2020: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 4
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Treatments in Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- leptin, obesity treatment, childhood obesity, appetite suppression, energy expenditure, adipocytes, hyperleptinemia
- MeSH terms
- Adipose Tissue, Animals, Humans, Islets of Langerhans, Obesity, Receptors, Cell Surface, Signal Transduction, Leptin, Ciliary Neurotrophic Factor, Mice, Rats, Receptors, Leptin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
